COVID-19 vaccination and HIV-1 acquisition.
作者信息
Logunov Denis Y, Livermore David M, Ornelles David A, Bayer Wibke, Marques Ernesto, Czerkinsky Cecil, Dolzhikova Inna V, Ertl Hildegund Cj
机构信息
NF Gamaleya National Research Centre for Epidemiology and Microbiology, Moscow, Russia.
Norwich Medical School, University of East Anglia, Norwich, UK.
出版信息
Lancet. 2022 Apr 9;399(10333):e34-e35. doi: 10.1016/S0140-6736(22)00332-4.
Abstract
摘要
相似文献
1
COVID-19 vaccination and HIV-1 acquisition.
Lancet. 2022 Apr 9;399(10333):e34-e35. doi: 10.1016/S0140-6736(22)00332-4.
2
COVID-19 vaccination and HIV-1 acquisition - Authors' reply.
Lancet. 2022 Apr 9;399(10333):e36. doi: 10.1016/S0140-6736(22)00329-4.
3
Mandatory COVID-19 Vaccination: Lessons from Tuberculosis and HIV.
Health Hum Rights. 2022 Jun;24(1):85-91.
4
Antibody and T-cell responses elicited by coronavirus disease 2019 vaccination in people with HIV-1: the case of late presenters.
AIDS. 2023 Aug 1;37(10):1625-1627. doi: 10.1097/QAD.0000000000003624.
5
COVID-19 Vaccine Uptake Among People Living with HIV.
AIDS Behav. 2022 Jul;26(7):2224-2228. doi: 10.1007/s10461-021-03570-9. Epub 2022 Jan 7.
6
Effectiveness of COVID-19 vaccination among people living with HIV during a COVID-19 outbreak.
J Microbiol Immunol Infect. 2022 Jun;55(3):535-539. doi: 10.1016/j.jmii.2022.04.006. Epub 2022 May 5.
7
Do not repeat mistakes from HIV in COVID-19 response.
Lancet HIV. 2021 Feb;8(2):e59. doi: 10.1016/S2352-3018(21)00001-1. Epub 2021 Jan 22.
8
SARS-CoV-2 vaccination in people with HIV.
Lancet HIV. 2021 Aug;8(8):e455-e456. doi: 10.1016/S2352-3018(21)00128-4. Epub 2021 Jun 18.
9
[SARS-CoV-2 vaccination in people living with HIV].
MMW Fortschr Med. 2022 Jun;164(Suppl 2):34-39. doi: 10.1007/s15006-022-1021-x.
10
COVID-19 Vaccination Uptake and Hesitancy in a National Sample of Australian Gay and Bisexual Men.
AIDS Behav. 2022 Aug;26(8):2531-2538. doi: 10.1007/s10461-022-03603-x. Epub 2022 Jan 31.
引用本文的文献
1
Stigma Attitudes Toward HIV/AIDS From 2011 Through 2023 in Japan: Retrospective Study in Japan.
J Med Internet Res. 2025 May 12;27:e69696. doi: 10.2196/69696.
2
Binding of Natural Antibodies Generated after COVID-19 and Vaccination with Individual Peptides Corresponding to the SARS-CoV-2 S-Protein.
Vaccines (Basel). 2024 Apr 17;12(4):426. doi: 10.3390/vaccines12040426.
3
The Interrelationship between HIV Infection and COVID-19: A Review of the Literature.
Curr HIV Res. 2024;22(1):6-15. doi: 10.2174/011570162X282739231222062830.
4
Triple Burden: The Incorrigible Threat of Tuberculosis, HIV, and COVID-19.
Infect Disord Drug Targets. 2024;24(4):1-7. doi: 10.2174/0118715265259959231031104820.
5
Development of Nasal Vaccines and the Associated Challenges.
Pharmaceutics. 2022 Sep 20;14(10):1983. doi: 10.3390/pharmaceutics14101983.
本文引用的文献
1
Effectiveness of the first component of Gam-COVID-Vac (Sputnik V) on reduction of SARS-CoV-2 confirmed infections, hospitalisations and mortality in patients aged 60-79: a retrospective cohort study in Argentina.
EClinicalMedicine. 2021 Oct;40:101126. doi: 10.1016/j.eclinm.2021.101126. Epub 2021 Sep 12.
2
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.
Lancet. 2021 Feb 20;397(10275):671-681. doi: 10.1016/S0140-6736(21)00234-8. Epub 2021 Feb 2.
3
Use of adenovirus type-5 vectored vaccines: a cautionary tale.
Lancet. 2020 Oct 31;396(10260):e68-e69. doi: 10.1016/S0140-6736(20)32156-5. Epub 2020 Oct 19.
4
Distinct susceptibility of HIV vaccine vector-induced CD4 T cells to HIV infection.
PLoS Pathog. 2018 Feb 23;14(2):e1006888. doi: 10.1371/journal.ppat.1006888. eCollection 2018 Feb.
5
Immunology. Immune activation with HIV vaccines.
Science. 2014 Apr 4;344(6179):49-51. doi: 10.1126/science.1250672.
6
Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine.
N Engl J Med. 2013 Nov 28;369(22):2083-92. doi: 10.1056/NEJMoa1310566. Epub 2013 Oct 7.
7
Risk of immunodeficiency virus infection may increase with vaccine-induced immune response.
J Virol. 2012 Oct;86(19):10533-9. doi: 10.1128/JVI.00796-12. Epub 2012 Jul 18.
8
Decreased pre-existing Ad5 capsid and Ad35 neutralizing antibodies increase HIV-1 infection risk in the Step trial independent of vaccination.
PLoS One. 2012;7(4):e33969. doi: 10.1371/journal.pone.0033969. Epub 2012 Apr 4.
9
Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study.
Lancet Infect Dis. 2011 Jul;11(7):507-15. doi: 10.1016/S1473-3099(11)70098-6. Epub 2011 May 11.
10
Serological immunity to adenovirus serotype 5 is not associated with risk of HIV infection: a case-control study.
AIDS. 2011 Jan 14;25(2):153-8. doi: 10.1097/QAD.0b013e328342115c.
Zotero 插件